Minerva Neurosciences Inc NERV

NAS: NERV | ISIN: US6033801068   31/05/2024
2,550 USD (+9,44%)
(+9,44%)   31/05/2024

1 mei 2024 · Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates · Persbericht

27 februari 2024 · Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia · Persbericht

22 februari 2024 · Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates · Persbericht

7 november 2023 · Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates · Persbericht

1 augustus 2023 · Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates · Persbericht

28 juni 2023 · Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market · Persbericht

15 mei 2023 · Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates · Persbericht

10 mei 2023 · Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia · Persbericht

8 mei 2023 · Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023 · Persbericht

1 mei 2023 · Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia · Persbericht

8 maart 2023 · Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates · Persbericht

1 maart 2023 · Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023 · Persbericht

28 december 2022 · Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia · Persbericht

9 november 2022 · Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates · Persbericht

9 september 2022 · Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market · Persbericht

22 augustus 2022 · Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia · Persbericht

9 augustus 2022 · Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates · Persbericht

4 mei 2022 · Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates · Persbericht

7 april 2022 · Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia · Persbericht

1 maart 2022 · Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates · Persbericht

Mijn selecties